PharmaCyte Biotech, Inc. — Director's Dealing 2025

Nov 18, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Q/C TECHNOLOGIES, INC. (QCLS)
CIK: 0001321834
Period of Report: 2025-09-04

Reporting Person: PharmaCyte Biotech, Inc. (10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-09-04	Series H Convertible Preferred Stock	$	P	889865	Acquired		Common stock, par value $0.001 per share (889865)	Direct
2025-11-14	Warrants	$	P	889865	Acquired	2030-11-14	Common stock, par value $0.001 per share (889865)	Direct

Footnotes

F1: The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire.